We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
(-9.8%)
Cap. Flow
-$772M
Cap. Flow
% of AUM
-28.57%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$39.7M |
| 2 |
Humana
HUM
|
+$32.6M |
| 3 |
MAZE
Maze Therapeutics
MAZE
|
+$29.9M |
| 4 |
Avalo Therapeutics
AVTX
|
+$25.8M |
| 5 |
ALMR
Alamar Biosciences
ALMR
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$78.9M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$71.8M |
| 3 |
CG Oncology
CGON
|
+$66.7M |
| 4 |
argenx
ARGX
|
+$55.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.44% |
| 2 | Miscellaneous | 3.68% |
| 3 | Financials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLYM
26
Climb Bio
CLYM
$837M
| $36.5M | 1.35% |
2,797,375
+1,267,700
| +83% | +$13.1M |
|
27
CareDx
CDNA
$2.58B
| $34.8M | 1.29% |
1,220,602
-952,544
| -44% | -$20.7M |
|
|
MAZE
28
Maze Therapeutics
MAZE
$1.52B
| $34M | 1.26% |
+1,140,040
| New | +$29.9M |
|
|
DRUG
29
Bright Minds Biosciences
DRUG
$714M
| $34M | 1.26% |
483,822
-55,886
| -10% | -$4.39M |
|
30
Acadia Healthcare
ACHC
$2.66B
| $33.7M | 1.25% |
1,141,477
+495,577
| +77% | +$12.7M |
|
31
Nektar Therapeutics
NKTR
$2.48B
| $33.1M | 1.22% |
473,617
+250,916
| +113% | +$18.4M |
|
32
Corvus Pharmaceuticals
CRVS
$1.19B
| $31.8M | 1.18% |
2,126,298
+373,500
| +21% | +$5.18M |
|
33
Nurix Therapeutics
NRIX
$2.72B
| $31.2M | 1.15% |
1,286,769
-463,997
| -27% | -$7.9M |
|
34
Inspire Medical Systems
INSP
$1.78B
| $30.2M | 1.12% |
677,570
| – | – |
|
|
35
Avalo Therapeutics
AVTX
$1.05B
| $30.1M | 1.11% |
+1,629,182
| New | +$25.8M |
|
|
ALMR
36
Alamar Biosciences
ALMR
$2.13B
| $29.4M | 1.09% |
+1,083,983
| New | +$24.5M |
|
37
Danaher
DHR
$152B
| $28.7M | 1.06% |
150,627
+11,300
| +8% | +$2.05M |
|
38
Intuitive Surgical
ISRG
$132B
| $27.9M | 1.03% |
70,137
-7,160
| -9% | -$3.13M |
|
|
ORKA
39
Oruka Therapeutics
ORKA
$6.03B
| $26.5M | 0.98% |
+278,164
| New | +$18.5M |
|
|
AVLN
40
Avalyn Pharma
AVLN
$1.54B
| $26.4M | 0.98% |
+801,395
| New | +$23.1M |
|
41
Aveanna Healthcare
AVAH
$2.91B
| $26.3M | 0.97% |
3,065,106
+861,600
| +39% | +$6.07M |
|
|
BIOA
42
BioAge Labs
BIOA
$443M
| $25.3M | 0.94% |
1,033,129
-167,458
| -14% | -$3.03M |
|
43
Boston Scientific
BSX
$67.9B
| $25.1M | 0.93% |
587,567
+241,100
| +70% | +$13.1M |
|
44
Vera Therapeutics
VERA
$2.46B
| $24.2M | 0.9% |
564,724
+40,900
| +8% | +$1.52M |
|
45
Repligen
RGEN
$9.95B
| $24.2M | 0.89% |
177,100
+129,600
| +273% | +$15.9M |
|
46
Zura Bio
ZURA
$548M
| $23.5M | 0.87% |
3,980,295
-8,694
| -0.2% | -$41.4K |
|
47
Guardant Health
GH
$21.7B
| $22.2M | 0.82% |
147,850
-351,862
| -70% | -$38.3M |
|
48
Evolus
EOLS
$587M
| $21.9M | 0.81% |
3,155,209
+50,000
| +2% | +$295K |
|
49
Natera
NTRA
$47B
| $21.6M | 0.8% |
79,500
-49,500
| -38% | -$10.6M |
|
50
OrthoPediatrics
KIDS
$617M
| $21.1M | 0.78% |
1,100,370
| – | – |
|
Similar funds
CWM
M
AG
NIM
GC
BIAS
CCM
ACP
Braidwell's Q2 2026 Portfolio in Review
As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Humana worth $45.5M.
- Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
- Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
- Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
- Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
- Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
- Braidwell opened 24 new positions and closed 23 in Q2 2026.
- Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.
Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.